BCA2 is differentially expressed in renal oncocytoma: An analysis of 158 renal neoplasms

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 787-791

  Ehsani, Laleh ^a   Seth, Rishie ^c   Bacopulos, Stephanie ^c   Seth, Arun ^c   Osunkoya, Adeboye O ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

BCA2; Chromophobe renal cell carcinoma; Clear cell carcinoma; Papillary renal cell carcinoma; Renal oncocytoma

Indexed keywords

PROTEASOME; PROTEIN BCA2; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; RNF115 PROTEIN, HUMAN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; CELL CYCLE; DNA DAMAGE; DNA REPAIR; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; RENAL ONCOCYTOMA; ADENOCARCINOMA; CANCER STAGING; ENZYME IMMUNOASSAY; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; TISSUE MICROARRAY;

ADENOCARCINOMA, CLEAR CELL; ADENOMA, OXYPHILIC; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

MLCS; MLOWN;

EID: 84877289546     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0608-8     Document Type: Article

References (39)

1. Zippel L. Zur kenntnis der onkocytoma. Virchows Arch [A] Pathol Anat. 1942;308:360-82.
2. Klein MJ, Valesi QJ. Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm. Cancer. 1976;38:906-14.
3. Frydenberg M, Eckstein RP, Saalfield JA, et al. Renal oncocytoma - an Australian experience. Br J Urol. 1991;67:352-7.
4. Amin MB, Crotty TB, Tickoo SK, et al. Renal oncocytoma: a reappraisalof morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol. 1997;21:1-12.
5. Lieber MM, Tomera KM, Farrow GM. Renal oncocytoma. J Urol. 1981;125:481-5.
6. Perez-Ordonez B, Hamed G, Campbell S, et al. Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol. 1997;21:871-83.
7. Davis Jr CJ, Mostofi FK, Sesterhenn I, et al. Renal oncocytoma. Clinicopathological study of 166 patients. J Urogen Pathol. 1991;1:41-52.
8. Humphrey PA, Dehner LP, Pfeifer JD. Oncocytoma. The Washington Manual of Surgical Pathology. Lippincott, Williams and Wilkins, 2008;293-4.
9. Brahemi G, Kona FR, Fiasella A, et al. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. J Med Chem. 2010;53(7):2757-65.
10. Burger AM, Gao Y, Amemiya Y, et al. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res. 2005;65(22):10401-12.
11. Kuroda N, Kanomata N, Yamaguchi T, et al. Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma. Med Mol Morphol. 2011;44(2):111-5.
12. Kim SS, Choi YD, Shim MK, et al. Microscopic and nuclear morphometric findings of chromophobe renal cell carcinoma, renal oncocytoma, and tumor with overlapping histology. Ann Diagn Pathol. 2012;16(6):429-35.
13. Mathers ME, Pollock AM, Marsh C, O'Donnell M. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology. 2002;40:563-7.
14. Carrion R, Morgan BE, Tannenbaum M, Salup R, Morgan MB. Caveolin expression in adult renal tumors. Urol Oncol. 2003;21:191-6.
15. Garcia E, Li M. Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Am J Clin Pathol. 2006;125:392-8.
16. Rampino T, Gregorini M, Soccio G, et al. The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma. Am J Surg Pathol. 2003;27:779-85.
17. Patton KT, Tretiakova MS, Yao JL, et al. Expression of RON proto-oncogene in renal oncocytoma and chromophobe renal cell carcinoma. Am J Surg Pathol. 2004;28:1045-105.
18. Mazel PR, Exner M, Haitel A, et al. Expression of kidney-specifi c cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol. 2005;36:22-8.
19. Shen SS, Krishna B, Chirala R, Amato RJ, Troung LD. Kidney-specific cadherin: a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18:933-40.
20. Adley BP, Gupta A, Lin F, et al. Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2006;126:79-85.
21. Kuehn AK, Paner GP, Skinnider BF, et al. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol. 2007;31:1528-33.
22. Osunkoya AO, Cohen C, Lawson D, et al. Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol. 2009;40(2):206-10.
23. Fernández-Aceñero MJ, Cazorla A, Manzarbeitia F. Immunohistochemistry for the differential diagnosis of renal tumors with oncocytic features. Urol Oncol. 2011;29(5):545-9.
24. Hes O, Brunelli M, Michal M, et al. Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol. 2006;10:133-9.
25. Kunju LP, Wojno K, Wolf JS, Cheng L, Shah RB. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol. 2008;39:96-101.
26. Joazeiro CA, Weisseman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 2000;102:549-52.
27. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T. Control of IKBA proteolysis by the ubiquitin-proteasome pathway. Biochimie. 2001;83:351-6.
28. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene. 2004;23:1985-97.
29. Dohmen RJ. SUMO protein modification. Biochim Biophys Acta. 2004;1695:113-31.
30. Pickart CM, Ed dins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. 2004;1695:55-72.
31. Aragon L. Sumoylation: a new wrestler in the DNA repair ring. Proc Natl Acad Sci U S A. 2005;102:4661-2.
32. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776-89.
33. Denison C, Kirkpatrick DS, Gygi SP. Proteomic insights into ubiquitin and ubiquitin-like proteins. Curr Opin Chem Biol. 2005;9:69-75.
34. Yutaka A, Peter A, Arun S. Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res. 2008;6:1385-96.
35. Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem. 1998;67:425-79.
36. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004;40:2217-29.
37. Zhang Z, Liao B, Xu M, Jin Y. Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1. FASEB J. 2007;21:3042-51.
38. Burger AM, Kona F, Amemiya Y, et al. Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer. Open Cancer J. 2010;3(1):116-23.
39. Burger A, Amemiya Y, Kitching R, Seth AK. Novel ring E3 ubiquitin ligases in breast cancer. Neoplasia. 2006;8(8):689-95.